---
title: "Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304691682.md"
description: "Peter Kolchinsky and Rajeev Shah, controlling RA Capital Management, disclosed a 14.6% beneficial ownership stake in Bambusa Therapeutics via an SEC Schedule 13D filing dated Nov. 6, 2026. The holding comprises 7,429,758 shares acquired through open-market purchases following the company's IPO. While stating no immediate plans to change control, they reserve the right to discuss strategy and governance with management."
datetime: "2026-11-06T21:26:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304691682.md)
  - [en](https://longbridge.com/en/news/304691682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304691682.md)
generator: "portal-rs"
---

# Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics

**Peter Kolchinsky and Rajeev Shah Disclose 14.6% Stake in Bambusa Therapeutics**

Peter Kolchinsky and Rajeev Shah, who control RA Capital Management, L.P., disclosed beneficial ownership of 7,429,758 shares of Bambusa Therapeutics, Inc., equal to 14.6% of its common stock. Their Schedule 13D, dated Nov. 6, 2026, followed Bambusa’s Nov. 2 IPO and disclosed open-market purchases by the Fund on Oct. 30. The investors say they bought the shares for investment, not to change control, but may discuss Bambusa’s strategy and governance.

**Investor Intent**

The investors say they have no current plans to pursue changes covered by Schedule 13D’s specified actions. They may talk with Bambusa leaders, directors, shareholders and other parties about its operations, strategic direction, governance, capitalization, or possible business combinations and dispositions. RA Capital partner Derek DiRocco already serves on Bambusa’s board and will take part in regular board and management discussions as a director.

**Investor's Background**

RA Capital Management, L.P. provides investment management services to RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Peter Kolchinsky and Rajeev Shah control the general partner of RA Capital and may be treated as beneficial owners of securities managed by the firm. RA Capital Healthcare Fund is a private investment vehicle, and RA Capital directs voting and investment decisions for the shares reported in this filing.

Original SEC Filing: Bambusa Therapeutics, Inc. \[ BBTX \] - SCHEDULE 13D - Nov. 06, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BBTX.US](https://longbridge.com/en/quote/BBTX.US.md)

## Related News & Research

- [Bambusa Therapeutics Grants CEO Shanshan Xu 758,204 Performance-Based Restricted Stock Units](https://longbridge.com/en/news/304007383.md)
- [Bambusa Therapeutics Director Helmut Wolfgang Jeggle Reports $6 Million Common Share Acquisition](https://longbridge.com/en/news/304008064.md)
- [AI’s 48-Hour Stress Test Starts Now](https://longbridge.com/en/news/305878236.md)
- [Will Upper Stage Recovery Change SpaceX's (SPCX) Narrative](https://longbridge.com/en/news/305914563.md)
- [Sandisk (SNDK) Stock Could Be 42% Below Fair Value Following Data Center Regulation Fears](https://longbridge.com/en/news/305917622.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**